Quick Answer
PDS Biotechnology Corp reported Stockholders Equity of $9.25 million for fiscal year 2025.
PDS Biotechnology Corp Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $9.25M | -2.1% |
| 2025 | $9.45M | -40.8% |
| 2025 | $15.96M | -28.6% |
| 2025 | $22.36M | +17.7% |
| 2024 | $19.00M | -13.6% |
| 2024 | $22.00M | -28.8% |
| 2024 | $30.92M | -16.8% |
| 2024 | $37.18M | +42.3% |
| 2023 | $26.13M | +6.7% |
| 2023 | $24.48M | -24.5% |
| 2023 | $32.44M | -20.9% |
| 2023 | $41.01M | -6.8% |
| 2022 | $44.00M | -6.5% |
| 2022 | $47.06M | -8.5% |
| 2022 | $51.43M | -8.0% |
| 2022 | $55.87M | -11.6% |
| 2021 | $63.21M | -6.8% |
| 2021 | $67.86M | -7.0% |
| 2021 | $72.99M | +199.5% |
| 2021 | $24.37M | -10.2% |
| 2020 | $27.13M | +131.9% |
| 2019 | $11.70M | +666.1% |
| 2018 | -$2.07M | -239.0% |
| 2017 | -$609.5K | -100.7% |
| 2016 | $89.28M | -27.1% |
| 2015 | $122.48M | +540.0% |
| 2014 | -$27.83M | -81.3% |
| 2013 | -$15.35M | -100.6% |
| 2012 | -$7.65M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.45M | -57.0% | -40.8% |
| June 30, 2025 | $15.96M | -48.4% | -28.6% |
| March 31, 2025 | $22.36M | -39.9% | +17.7% |
| December 31, 2024 | $19.00M | -27.3% | -13.6% |
| September 30, 2024 | $22.00M | -10.1% | -28.8% |
| June 30, 2024 | $30.92M | -4.7% | -16.8% |
| March 31, 2024 | $37.18M | -9.3% | +42.3% |
| December 31, 2023 | $26.13M | -40.6% | +6.7% |
- PDS Biotechnology Corp showed a decrease of -2.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2012–2025 period, PDS Biotechnology Corp’s stockholders equity has grown by 220.9% (from -$7.65 million to $9.25 million).
- The most recent figure is from PDS Biotechnology Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: